IRVINE, CA -- (Marketwired) -- 06/04/14 -- Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today announced that it received two new China CFDA approvals for its Parathyroid Hormone (PTH) and Calcitonin products. The products will be distributed through a new China distribution channel unrelated to Biomerica's current distribution channel in China. Biomerica's new distributor for these is one of the top 3 leading Vitamin D test suppliers in China. Biomerica's PTH and Calcitonin tests are a strategic complement to the new distributor's existing Vitamin D sales.
Parathyroid hormone (PTH) is a hormone released by the parathyroid glands. These glands are responsible for managing calcium, vitamin D, and phosphorus levels in the blood and bones. PTH helps regulate calcium levels in the blood. In 2013, the number of vitamin D tests performed worldwide is estimated to be greater than 100 million and is expected to reach almost 140 million tests in 2015. Vitamin D testing in China is growing very rapidly but is still considered to be in the beginning stage of testing. The Institute of Medicine guidelines for dietary intake of vitamin D were meant to prevent the seasonal increase in PTH associated with lower vitamin D status. Consistently increased concentrations of PTH are associated with an increase in risk for osteoporosis in later life. Intact PTH is the most frequently ordered parathyroid hormone test. It is used to help diagnose the cause of a low or high calcium level and to help distinguish between parathyroid-related and non-parathyroid-related causes. Calcitonin is primarily used to help diagnose C-cell hyperplasia and medullary thyroid cancer, to evaluate the effectiveness of treatment, and to monitor those affected for recurrence.
"We are pleased to receive CFDA approval and open up a new distribution channel in China. Our PTH and Calcitonin products are a great fit for our new distribution partner's Vitamin D test," said Zackary Irani, Biomerica's Chief Executive Officer.
About Biomerica (OTCBB: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for diabetes, gastrointestinal disease and esoteric testing.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to intended launch dates, expected improvements in performance, new product introductions, sales potential, market size, continued growth, favorable positions, expansion, expected approvals, leading market positions, expanded distribution, anticipated increases in sales or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.